[Financial News] "Quantum Eyes Looking into the Heart"...AMCG Enters KONEX

☞ Go to article

AMCG, a heart disease diagnostic solution company using biomagnetic field measurement technology, has been listed on KONEX, the company announced on the 16th.

The Korea Exchange approved AMCG's new listing application submitted on November 20 last year, and trading has begun. The designated advisor for this listing is Daishin Securities.

Founded in 2021, AMCG has pursued commercialization after receiving Superconducting Quantum Interference Device (SQUID) technology and Magnetocardiography (MCG) system technology from the Korea Research Institute of Standards and Science (KRISS), a national standards agency. It has since obtained item approvals from both domestic and US food and drug administrations and is engaged in the heart disease diagnostic medical device business.

The first released product 'MCG-S' is currently installed in two hospitals and is undergoing post-marketing phase clinical trials to "evaluate the accuracy of MCG Scan for patients suspected of coronary artery disease."

Existing heart disease examination methods require step-by-step application of stress electrocardiogram, echocardiography, cardiac nuclear medicine (SPECT) examination, and cardiac CT to obtain accurate results. This results in long time requirements and exposure to radiation risks.

AMCG's magnetocardiography scanner measures extremely tiny magnetic signals (one billionth of the Earth's magnetic field) from the myocardium using SQUID (Superconducting Quantum Interference Device), a next-generation quantum sensor, to provide diagnostic information, and is attracting attention as a next-generation heart disease diagnostic device.

CEO Seo Yong-sung said, "Based on the clinical results, we are focusing on obtaining new medical technology assessment next year and health insurance coverage in 2026."

The follow-up model, 'MCG-F', is being developed with lightweight technology. This product is planned to obtain domestic item approval in 2025 and introduce it to the rapidly growing health check-up market.

CEO Seo said, "Despite the unfavorable investment conditions this year, we have attracted 10 billion won in investment," adding, "We have received recognition for our technology and business potential, securing a total of 1.2 billion won in government contributions through Scale-up TIPS (R&D) projects."

He continued, "The KONEX market listing will be an opportunity to grow as a global company in the field of early diagnosis of heart disease," emphasizing, "Our goal is to transfer to KOSDAQ within 2 years."

[Financial News Reporter Jung Myung-jin]